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The publication date of this issue of ACKD, July-August 2019, is almost exactly 30 years after the 
approval by the Food and Drug Administration (FDA) of epoetin alfa in June 1989. There has been 
considerable evolution in the treatment of anemia in patients with CKD since that time despite the fact 
that erythropoietic stimulating agents (ESAs) remain the mainstay of that therapy. In the 1990s, we 
discovered the necessity of adequate iron supplementation to achieve the targeted erythropoietic response 
to ESAs. In the 2000s, we discovered that normalization of hemoglobin (Hb) levels in patients with CKD 
is associated with major adverse cardiovascular events (MACEs) compared to Hb targets in the 9-
11.5 g/dL range. In the 2010s, we have seen increased choice of ESAs including longer acting agents and 
biosimilar forms; newer options for administration of iron including more bioavailable oral agents, a 
dialysate formulation, and evidence supporting the efficacy and safety of more proactive intravenous (IV) 
administration in hemodialysis (HD) patients; and an increased understanding of the role of hepcidin in 
the phenomenon called “ESA resistance.” However, all of these advances have been refinements to an 
ESA-centric anemia treatment model in CKD without much in the way of disruptive technology. The 
hypoxia-inducible factor (HIF) stabilizers are that disruptive technology which, as of 2019, puts us at the 
threshold (or possibly precipice) of the first true revolution in anemia management in 3 decades. 
Where We Are 
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In the wake of randomized controlled trials comparing Hb targets in the 9-11.5 g/dL to those in the 13-
15 g/dL range, there remains considerable controversy regarding benefit vs risk of ESA therapy; practice 
guidelines, product labels, and payment policy leave us with a one-size-fits-all approach to anemia 
management. Patient preferences have been eliminated from this treatment model despite the fact that 
fatigue (which may or may not be anemia related) is one of the most common symptoms reported by 
patients with CKD.1 Many patients may accept the risk of higher MACE at a target Hb level greater than 
that allowed by ESA dosing algorithms, FDA label guidance, and payment policy if the patients were 
given adequate information to make that choice. The Kidney Disease: Improving Global Outcomes 
guidelines acknowledge the importance of informed patient-centered decision making in this respect with 
a ceiling target Hb of 13 g/dL for those patients whose lifestyles would benefit from a higher Hb level and 
are willing to accept the MACE risk.2 Since Hb > 12 g/dL is no longer a metric in either the US ESRD 
Quality Incentive Program or Dialysis Facility Compare, payment and public reporting policy should not 
be a disincentive to this component of patient-centered care. 
It is clear that intermittent large doses of IV iron are an unphysiologic approach to iron replacement in 
anemic patients with iron deficiency. In non-dialysis dependent CKD (NDD-CKD) and peritoneal dialysis 
patients, traditional oral iron supplements have had variable success in repleting iron stores; ferric citrate3 
and those in the development pipeline (ferric maltol and sucrosomial/liposomal forms of oral iron) offer 
the promise of better bioavailability. Nonetheless, even these newer agents are not universally effective, 
and IV iron administration may be required. The latest generation of IV iron supplements such as 
ferumoxytol, ferric carboxymaltose, and iron isomaltoside (not yet approved in the United States) offer 
the advantages to NDD-CKD patients of larger doses per session which may decrease visits to the 
infusion center and venipunctures to precious venous real estate for future vascular access. For HD 
patients, IV iron is required in about 80% due to ongoing iron losses averaging 2-3 g/y.4 The most 
physiologic way to replace these iron losses would be with small doses of iron administered frequently 
since only 3-4 mg iron is in the circulation bound to transferrin at any given time. Nonetheless, the most 
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common protocols for administration of IV iron in HD units are in doses exceeding 50 mg per session 
because that is how the iron is packaged and less frequent doses of more iron require less nursing time. 
There are data suggesting that newer forms of iron administered in smaller doses more frequently 
decrease IV iron requirements in HD patients, thereby potentially decreasing the long-term toxicity of IV 
iron which may include tissue iron accumulation, oxidative stress to vascular endothelium, and infection 
risk. These newer forms of iron include oral ferric citrate3 and ferric pyrophosphate citrate administered 
via the dialysate.5 With or without such supplements, IV iron remains a mainstay of anemia treatment in 
HD patients. The controversy regarding the benefit vs risk of more aggressive IV iron replacement 
protocols has been addressed by the recently published Proactive IV Iron Therapy in Hemodialysis 
Patients (PIVOTAL) study which demonstrated that a proactive IV iron replacement protocol with a 
serum ferritin ceiling of 700 ng/mL was more effective (19% reduction in ESA dose at similar target Hb 
level) and safer (lower MACE) than a reactive IV iron replacement protocol with a ferritin floor of 
200 ng/dL.6 This offers some comfort to practitioners in the United States who have been prescribing 
sufficient IV iron to HD patients such that the mean serum ferritin is >800 ng/mL7 despite Kidney 
Disease: Improving Global Outcomes recommendations that IV iron not be administered if the serum 
ferritin is >500 ng/mL.2 How the results of the PIVOTAL study will affect future clinical practice remains 
to be seen. 
The development of longer acting ESAs including darbepoetin alfa and methoxy polyethylene glycol-
epoetin beta (CERA) would appear to be of more relevance to NDD-CKD and peritoneal dialysis patients 
who must receive their ESA subcutaneously and may need to visit a healthcare facility for the injection. 
Nonetheless, these longer acting agents have found significant market penetration in the HD patient 
population, driven by favorable contracting terms between the supplier and dialysis organizations and less 
nursing time required for administration. As of April 2018, according to the Dialysis Outcomes and 
Practice Patterns Study (DOPPS), epoetin alfa had 37.2%, darbepoetin alfa had 24.3%, and CERA had 
38.5% market share among US HD patients.8 Of some concern is a recent publication which 
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retrospectively examined Japanese dialysis patients receiving ESAs.9 It compared mortality risk between 
patients receiving short-acting ESAs (epoetin including a biosimilar form) and long-acting ESAs 
(darbepoetin and CERA). The authors used sophisticated statistical modeling to minimize the chance of 
residual confounding. Irrespective of the adjustment model, patients receiving long-acting ESAs had a 
higher rate of death from all causes, cardiovascular disease, cardiac disease, stroke, non-cardiovascular 
disease, stroke, and malignancy. The statistically significant hazard ratio persisted for all patient sub-
groups except those with the lowest ESA dose and lowest erythropoietin resistance index, suggesting that 
the toxicity of long-acting ESAs is dose related. It should be noted that a previous study by Winkelmayer 
and colleagues10 comparing long-term outcomes among US dialysis facilities using primarily darbepoetin 
vs epoetin found no differences between the groups. Only a long-term randomized controlled trial 
comparing short-acting vs long-acting ESAs can conclusively prove a cause and effect relationship 
between ESA duration of action and mortality risk. MIRCERA PASS (post-approval safety study) is an 
8-year non-inferiority trial (median follow-up 3.4 years), yet to be published, comparing CERA with 
short-acting ESAs. The results were presented at ASN 2018 Kidney Week and revealed no difference 
between the two groups in MACE or all-cause mortality.11 
Where We're Going 
The discovery of hepcidin has been a breakthrough in our understanding of the control of iron absorption 
and internal disposition. This control system likely evolved as a defense mechanism against siderophilic 
pathogens; the inflammatory response which stimulates hepcidin leads to a reduction in blood iron levels 
through decreased absorption of iron from the gastrointestinal tract and decreased release of iron from 
macrophages where it is stored. This “anemia of chronic disease” is particularly common in CKD, an 
inflammatory state, and results in iron restricted erythropoiesis with or without ESA therapy. Both high 
ESA doses and high iron doses may be required to overcome the decreased delivery of iron to the 
erythroid marrow in the presence of high hepcidin levels, leading to potential toxicity from both these 
therapies. A variety of agents are in the development pipeline targeting the action of hepcidin in anemic 
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patients with CKD. These include monoclonal antibodies directed against hepcidin itself, agents directed 
against pro-inflammatory cytokines that stimulate hepcidin production such as interleukin-6 and 
transforming growth factor-α, and agents directed against intermediaries in the hepcidin signaling 
pathway. 
HIF stabilizers belong to a new class of orally administered drugs to treat anemia in patients with CKD.12 
HIF is present in nearly all tissues and constitutes the body's natural mechanism to adapt to hypoxic 
conditions. HIF is a heterodimer consisting of an alpha and beta subunit. The alpha subunit is rapidly 
degraded by a proline hydroxylase (PH) enzyme in the presence of oxygen, thereby preventing the 
heterodimerization with the beta subunit and its transcriptional effects on over 4000 genes, depending on 
the tissue. Activation of these genes leads to increased red blood cell production through increased 
synthesis of erythropoietin and the erythropoietin receptor as well as increased synthesis of a variety of 
iron handling proteins including transferrin, transferrin receptor, duodenal cytochrome B, divalent metal 
transporter-1, and ceruloplasmin. The net effect is a more “complete” stimulation of erythropoiesis than 
can be achieved by ESAs alone which do not affect iron metabolism. However, HIF stabilizers also 
stimulate a variety of genes not affecting erythropoiesis including those which affect angiogenesis, 
glucose metabolism, extracellular matrix production, and cellular proliferation. The HIF stabilizers under 
development have attempted to achieve specificity for erythropoiesis by targeting specific PH enzymes 
and with pharmacokinetics that allow for periods between doses during which there is no PH inhibition so 
that the effect of these agents on non-targeted genes can be minimized. There are 3 HIF stabilizers 
currently under development in the United States: roxadustat, vadadustat, and daprodustat. Roxadustat 
has a half-life of 12-13 hours and has been shown to be effective in raising Hb levels when administered 3 
times weekly; vadadustat and daprodustat have half-lives of around 4 hours and are administered daily. 
Multiple phase 2 studies have been published with all 3 agents demonstrating comparable efficacy in 
maintaining Hb levels within target range when dialysis patients are switched from ESAs and in raising 
Hb levels to target range in ESA-naïve dialysis and NDD-CKD patients. Because of their beneficial 
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effects on iron metabolism which lead to an increase in oral iron absorption, increased release of stored 
iron from macrophages, and increased transport of iron to the erythroid marrow, HIF stabilizers have been 
shown to be equally effective with oral or IV iron in the short term,13 although it unlikely this can be 
sustained over the long term in HD patients given their ongoing iron losses. The use of HIF stabilizers has 
been shown to decrease hepcidin levels, although this is thought to be mediated by increased 
erythroferrone released by RBC precursors in the setting of accelerated erythropoiesis, not a direct effect 
of the HIF stabilizers. Nonetheless, HIF stabilizer therapy has demonstrated comparable responsiveness in 
raising Hb levels among patients with normal or high CRP levels, the latter being a surrogate for the 
inflammatory conditions that typically lead to “ESA resistance.”14 Chinese phase 3 studies of roxadustat 
presented at 2018 ASN Kidney Week14,15 demonstrated efficacy non-inferiority to ESA in end-stage 
kidney disease (ESKD) patients and superiority to placebo in NDD-CKD patients. However, these studies 
were not adequately powered for MACE outcomes (<1000 patients, 6 months of duration). Roxadustat 
has been approved for use in China by Chinese regulatory authorities. 
Prior to the release of long-term (3 year) safety data, it is difficult to predict what the role of HIF 
stabilizers will be in the treatment of anemia in patients with CKD. Even with 3-year MACE data, there 
may still be reservations regarding the widespread adoption of these agents because it may take more than 
3 years to determine their non-MACE effects such as angiogenesis (tumor growth, diabetic retinopathy), 
altered glucose metabolism, rate of renal function decline in NDD-CKD patients, and pulmonary 
hypertension. The appeal of an oral anemia therapy in non-HD patients is undeniable, even without longer 
term safety data. A reasonable approach in the non-HD population would be to discuss the risks and 
benefits of ESAs vs HIF stabilizers so the patient can make an informed decision balancing convenience 
with possible unknown risk. The same risk vs benefit discussion applies to the HD population where the 
motivation to abandon the parenterally administered ESA class of drugs with 30 years clinical experience 
is less compelling except if the patient is ESA resistant. 
How Will This Be Paid For? 
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No discussion of pharmacotherapy should occur without consideration of cost and payment. The cost of 
treating anemia in patients with CKD is highly visible to payers and is the major driving force in 
Medicare's moving from a fee-for-service to a prospective payment system (PPS or “bundling”) for 
ESKD patients in 2011. Despite more conservative ESA use following the implementation of the PPS, it 
is estimated from cost reports that ESAs for ESKD patients in the United States exceeded $1.7 billion in 
2016.16 Payment for ESAs in NDD-CKD patients is determined by the patient's prescription drug plan, 
many of which have high co-pays that may be a barrier to ESA use. Almost all pharmacy benefit 
managers require prior authorization for ESAs, and many are now requiring that the patient receive 
epoetin alfa-epbx, the biosimilar epoetin alfa approved in the United States which is their least expensive 
ESA, unless there is a compelling reason why the patient should receive a brand name ESA. The pricing 
of HIF stabilizers has yet to be determined, so a value proposition cannot be quantified. Because HIF 
stabilizers will be approved by the FDA during or after 2020, their use in ESKD patients will quality for 
the “transitional drug add-on payment adjustment (TDAPA)” to the ESKD PPS.17 Each HIF stabilizer 
will be paid for by the Centers for Medicare and Medicaid Services outside the dialysis payment “bundle” 
for 2 years following its approval by the FDA. In other words, for those 2 years the HIF stabilizer will be 
paid for through Medicare part D or Medicaid and will not cost the dialysis provider anything. The 
bundled payment for patients using an HIF stabilizer through TDAPA will be reduced by the average cost 
of ESA per treatment, which is around $30. Thus, if a patient's ESA dose costs more than an average of 
$30 per treatment, the dialysis facility will save money if an HIF stabilizer is used rather than an ESA. 
This provides a perverse economic, non-clinical, non-patient-centered incentive to use HIF stabilizers 
which it is hoped will be resisted. After its 2-year TDAPA period, each HIF stabilizer will not go into the 
dialysis payment bundle, but will rather be charged to Centers for Medicare and Medicaid Services by the 
dialysis provider as an “outlier payment” which is not fully reimbursed. At that point there may again be a 
perverse economic incentive to return to ESAs which remain in the bundle, or there may be competition 
which brings the price of all anemia treatments down. 
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Ultimately, the treatment of anemia in patients with CKD is a microcosm of Berwick's triple aim18: (1) 
population-driven, evidence-based, one-size-fits-all medicine with performance metrics; (2) patient-
centered decision making and satisfaction with individual outcomes; and (3) the quest for payment 
policies which align incentives. The dawn of innovative anemia treatments gives stakeholders 
(physicians, health systems, dialysis organizations, payers, and patients) a rare opportunity to reassess the 
balance of this dynamic interplay and to chart a course that, while being evidence-based, encourages 
patients to assume a greater role in therapeutic decision making as new product choices become available, 
less constrained by unyielding clinical performance metrics, and within the guardrails of fiscal 
responsibility that recognizes the total, long-term cost of care and not just the price tag of today's 
medications. 
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